BIIB241213P144000
- 0.00
- 0.000.00%
Biogen Newsroom
Biogen ALS Drug Needs to Be Covered by MA Plans, CMS Says
Is Biogen Inc.'s (NASDAQ:BIIB) Stock Price Struggling As A Result Of Its Mixed Financials?
N-Lorem Foundation's Nano-rare Patient Colloquium Draws More Than 750 Attendees, Reinforcing Need for Treatment Options for People With Nano-rare Illnesses
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can XAI, Nvidia Help Stabilize Trajectory?
MicroStrategy Stock Could Get Added to the Nasdaq 100 Because of a Quirk
Biogen Reinstated With a Neutral at BofA
BofA Restarts Coverage of 11 Large-cap Biopharmas
B of A Securities Reinstates Neutral on Biogen, Announces $178 Price Target
Biogen Cut at Jefferies as '2025 Has a Tough Setup'
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Biogen Analyst Ratings
Jefferies Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $180
Biogen's Modest Growth Prospects and Revenue Challenges Highlighted in Hold Rating
Express News | Biogen : Jefferies Cuts to Hold From Buy
Biogen Appoints Tim Power as Head of Investor Relations
Stocks With Best Odds of Risk-adjusted Returns Deserve Attention: Goldman Sachs
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Biogen (BIIB) and Edwards Lifesciences (EW)
Morgan Stanley Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $192
GeneDx Announces Biogen, Praxis Precision Medicines And Stoke Therapeutics As The Founding Partners To Its Patient Access Program For Pediatric Epilepsy, Which Provides Access To Whole Exome Sequencing.